Fresenius Kabi is a focused healthcare company committed to improving the health of the critically and chronically ill.

Fresenius Kabi's core business segments are infusion therapy and clinical nutrition and the company is a leader in Europe in these segments, and in its most important countries in Asia Pacific and Latin America.

Products

Fresenius' infusion therapy product portfolio comprises infusion solutions for fluid substitution, blood volume replacement and intravenously administered drugs as well as the respective medical technical products. Infusion therapy products are essential medications, which are mainly used in surgery and in intensive and emergency medicine.

In the field of clinical nutrition, Fresenius Kabi has a wide range of products for enteral (via the gastrointestinal tract) as well as parenteral (i.v. administered) nutrition including devices where necessary.

Within infusion therapy and clinical nutrition businesses Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients in and outside the hospital. Recently Fresenius Kabi decides to broaden its portfolio by adding i.v. Generics for hospital use in the field of antibiotics, anesthesia and pain management.

Fresenius Kabi is active in the field of transfusion technology, supplying blood processing systems as well as blood bags and filters and has achieved leading positions in these markets.

With its philosophy "Caring for life" and a broad product portfolio, the company aims at improving the quality of life of patients all over the world.

Fresenius Kabi employs more than 16,000 people worldwide and has a global network of 50 sales organizations and 40 production sites. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius AG. For further information please visit www.fresenius-kabi.com.

Fresenius Kabi has the ability to incorporate formulation, clinical supplies, contract manufacturing and regulatory support through collaborative alliances.

Fresenius Kabi offers contract manufacturing services of i.v. solutions in glass- or plastic packaging (ampouls, vials, bottles or bags), see also www.fresenius- productpartnering.com. Commercial products for intravenous use are currently being manufactured internationally at various Fresenius Kabi facilities.

 Fresenius Kabi has developed a new drug delivery technolgy called HESylation Technology. For detail please refer to www.fresenius-kabi.com.